Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares, rose in value on Wednesday, June 18, with the stock price down by -6.92% to the previous day’s close as strong demand from buyers drove the stock to $0.24.
Actively observing the price movement in the last trading, the stock closed the session at $0.26, falling within a range of $0.2315 and $0.2606. The value of beta (5-year monthly) was 1.372. Referring to stock’s 52-week performance, its high was $3.10, and the low was $0.15. On the whole, PCSA has fluctuated by 0.04% over the past month.
With the market capitalization of Processa Pharmaceuticals Inc currently standing at about $2.88 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PCSA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PCSA currently trading nearly -16.12% and -7.65% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.71, while the 7-day volatility ratio is showing 17.90% which for the 30-day chart, stands at 10.81%. Furthermore, Processa Pharmaceuticals Inc (PCSA)’s beta value is 1.37, and its average true range (ATR) is 0.09.
A comparison of Processa Pharmaceuticals Inc (PCSA) with its peers suggests the former has fared considerably weaker in the market. PCSA showed an intraday change of -6.92% in last session, and over the past year, it shrunk by -86.17%%.
Data on historical trading for Processa Pharmaceuticals Inc (NASDAQ:PCSA) indicates that the trading volumes over the past 10 days have averaged 65.61 and over the past 3 months, they’ve averaged 13.63 million. According to company’s latest data on outstanding shares, there are 11.88 million shares outstanding.
Nearly 12.12% of Processa Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 1.44% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.75 million shares as on 2025-05-30, resulting in a short ratio of 0.26. According to the data, the short interest in Processa Pharmaceuticals Inc (PCSA) stood at 663.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 70227.0. The stock has fallen by -72.62% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PCSA stock heading into the next quarter.
